[1] |
Wheaton AG, Liu Y, Croft JB, et al. Chronic obstructive pulmonary disease and smoking status—United States, 2017[J]. Morb Mortal Wkly Rep, 2019, 68: 533-538.
|
[2] |
Chang D, Sharma L, Cruz CSD. Chitotriosidase: a marker and modulator of lung disease[J]. Eur Respir Rev, 2020, 29: 190143. doi: 10.1183/16000617.0143-2019.
|
[3] |
Aminuddin F, Akhabir L, Stefanowicz D, et al. Genetic association between human chitinases and lung function in COPD[J]. Hum Genet, 2012, 131: 1105-1114.
|
[4] |
Dunne AE, Kawamatawong T, Fenwick PS, et al. Direct inhibitory effect of the PDE4 inhibitor roflumilast on neutrophil migration in chronic obstructive pulmonary disease[J]. Am J Respir Cell Mol Biol, 2019, 60: 445-453.
|
[5] |
van Eijk M, Scheij SS, van Roomen CPAA, et al. TLR- and NOD2-dependent regulation of human phagocyte-specific chitotriosidase[J]. FEBS Lett, 2007, 581: 5389-5395. doi: 10.1016/j.febslet.2007.10.039.
|
[6] |
Lee CG, Herzog E, Ahangari F, et al. Chitinase 1 is a biomarker for and therapeutic target in scleroderma-associated interstitial lung disease that augments TGF-1 signal-ing[J]. J Immunol, 2012, 189: 2635-2644. doi: 10.4049/jimmunol.1201115.
|
[7] |
Spadaccini M, D'Alessio S, Peyrin-Biroulet L, et al. PDE4 inhibition and inflammatory bowel disease: a novel therapeutic avenue[J]. Int J Mol Sci, 2017, 18: 1276. doi: 10.3390/ijms18061276.
|
[8] |
Méhats C, Jin SL, Wahlström J, et al. PDE4D plays a critical role in the control of airway smooth muscle contraction[J]. FASEB J, 2003, 17: 1831-1841.
|
[9] |
李天水, 张成, 王广发, 等. 磷酸二酯酶4D基因单核苷酸多态性与COPD相关性研究[J]. 国际呼吸杂志, 2017, 37: 23-29. doi: 10.3760/cma.j.issn.1673-436X.2017.01.004.
|
[10] |
陈祥银,程显声,徐希胜,等. 吸烟者血清α1-抗胰蛋白酶、中性粒细胞弹性蛋白酶及组胺的变化[J]. 基础医学与临床, 2003, 4: 458-458.
|
[11] |
Smolonska J, Wijmenga C, Postma DS, et al. Meta-analyses on suspected chronic obstructive pulmonary disease genes: results from meta-analyses[J]. Am J Respir Crit Care Med, 2009, 180: 618-631. doi: 10.1164/rccm.200905-0722OC.
|